Palvella says Phase 2 TOIVA trial shows QTORIN rapamycin cuts venous malformation bleeding

Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc.

PVLA

0.00
  • Palvella Therapeutics disclosed new Phase 2 TOIVA trial results for topical QTORIN rapamycin in cutaneous venous malformations, presented at Society for Investigative Dermatology annual meeting.
  • Study readout showed improvement in bleeding among patients who entered trial with active bleeding, supporting potential use in a symptom that can drive medical visits and procedures.
  • Patients also reported high treatment satisfaction, aligning with clinician-assessed improvements and strengthening positioning for later-stage development.
  • Management framed program as a potential first FDA-approved option for cutaneous venous malformations in US, a claim that could shape commercial strategy if confirmed in future trials.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605150730PRIMZONEFULLFEED9720962) on May 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.